We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+0.9%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$19.9B
AUM Growth
-$564M
(-2.7%)
Cap. Flow
+$537M
Cap. Flow
% of AUM
2.69%
Top 10 Holdings %
Top 10 Hldgs %
34.1%
Holding
863
New
72
Increased
399
Reduced
357
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kinross Gold
KGC
|
+$280M |
| 2 |
Compañía de Minas Buenaventura
BVN
|
+$273M |
| 3 |
SLB Ltd
SLB
|
+$80.3M |
| 4 |
Wheaton Precious Metals
WPM
|
+$78.2M |
| 5 |
Royal Gold
RGLD
|
+$64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$62.5M |
| 2 |
Sibanye-Stillwater
SBSW
|
+$58.5M |
| 3 |
B
Barrick Mining
B
|
+$53.5M |
| 4 |
TSMC
TSM
|
+$49.5M |
| 5 |
Franco-Nevada
FNV
|
+$32.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 57.3% |
| 2 | Energy | 10.02% |
| 3 | Healthcare | 5.89% |
| 4 | Technology | 5.52% |
| 5 | Financials | 3.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Sociedad Química y Minera de Chile
SQM
$19.7B
| $13.7M | 0.07% |
357,139
+24,314
| +7% | +$1.05M |
|
202
Sarepta Therapeutics
SRPT
$1.72B
| $13.6M | 0.07% |
124,325
+15,763
| +15% | +$1.97M |
|
203
Goldgroup Mining Inc.
GORO
$157M
| $13.6M | 0.07% |
3,389,929
-808,571
| -19% | -$3.64M |
|
204
Marvell Technology
MRVL
$170B
| $13.4M | 0.07% |
827,273
-392,398
| -32% | -$6.5M |
|
205
GSK
GSK
$104B
| $12.6M | 0.06% |
264,646
-9,392
| -3% | -$463K |
|
206
Toro Company
TTC
$9.03B
| $12.5M | 0.06% |
224,392
-277
| -0.1% | -$16.1K |
|
|
NVO
207
Novo Nordisk
NVO
$220B
| $12.5M | 0.06% |
541,832
-8,818
| -2% | -$196K |
|
|
NE
208
DELISTED
Noble Corporation
NE
| $12.4M | 0.06% |
4,721,182
+1,817,440
| +63% | +$8.63M |
|
209
Laureate Education
LAUR
$5.24B
| $12.2M | 0.06% |
801,800
+231,600
| +41% | +$3.47M |
|
210
AstraZeneca
AZN
$264B
| $12.2M | 0.06% |
160,176
-17,743
| -10% | -$1.39M |
|
211
Novartis
NVS
$297B
| $12.1M | 0.06% |
157,844
-20,371
| -11% | -$1.59M |
|
212
Sanofi
SNY
$106B
| $12M | 0.06% |
276,075
-35,016
| -11% | -$1.54M |
|
213
Charles River Laboratories
CRL
$10.8B
| $11.4M | 0.06% |
100,939
+6,782
| +7% | +$849K |
|
|
SLCA
214
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $11.4M | 0.06% |
1,118,172
+322,524
| +41% | +$4.7M |
|
215
ICL Group
ICL
$6.66B
| $11.1M | 0.06% |
1,959,971
+48,603
| +3% | +$287K |
|
216
Oil States International
OIS
$513M
| $11M | 0.06% |
771,202
+278,329
| +56% | +$6.4M |
|
|
SUPV
217
Grupo Supervielle
SUPV
$854M
| $11M | 0.06% |
1,267,386
-32,000
| -2% | -$260K |
|
|
GRFS
218
Grifois
GRFS
$5.28B
| $10.8M | 0.05% |
586,901
-5,596
| -0.9% | -$111K |
|
219
Lowe's Companies
LOW
$119B
| $10.3M | 0.05% |
111,728
-271
| -0.2% | -$26.1K |
|
220
Credicorp
BAP
$31B
| $10.3M | 0.05% |
46,353
-41,430
| -47% | -$9.16M |
|
221
Viatris
VTRS
$20.6B
| $10.2M | 0.05% |
374,068
+47,220
| +14% | +$1.53M |
|
222
TJX Companies
TJX
$173B
| $10.2M | 0.05% |
228,786
+7,892
| +4% | +$399K |
|
|
CNP.PRB
223
DELISTED
CenterPoint Energy, Inc. Depositary Shares Each Representing a 1/20th Interest in a Share of 7.00% S
CNP.PRB
| $10.1M | 0.05% |
+201,263
| New | +$10.1M |
|
224
iShares Core US Aggregate Bond ETF
AGG
$138B
| $9.92M | 0.05% |
93,195
+46,056
| +98% | +$4.83M |
|
225
Vanguard Total Bond Market
BND
$158B
| $9.92M | 0.05% |
125,202
+61,946
| +98% | +$4.84M |
|
Similar funds
DAM
VanEck Associates's Q4 2018 Portfolio in Review
As of Q4 2018, VanEck Associates held 863 positions worth $19.9B, down 2.7% from $20.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
VanEck Associates's Q4 2018 filing shows 72 new, 399 increased, 357 reduced and 29 closed positions. Its largest new stake was Equifax: 224,466 shares worth $20.9M. The largest sale was Newmont, an estimated $62.5M.
By sector, the portfolio is most concentrated in Materials at 57% of assets, up from 48% a quarter earlier, followed by Energy and Healthcare.
- VanEck Associates's largest Q4 2018 buy was Equifax: 224,466 shares worth $20.9M.
- VanEck Associates added most to Kinross Gold in Q4 2018, an estimated $280M increase.
- VanEck Associates's biggest Q4 2018 reduction was Newmont, cutting an estimated $62.5M.
- VanEck Associates fully exited Energen in Q4 2018, selling an estimated $23.2M.
- VanEck Associates's ten largest holdings make up 34% of its $19.9B portfolio in Q4 2018.
- VanEck Associates opened 72 new positions and closed 29 in Q4 2018.
- VanEck Associates's portfolio value fell 2.7% quarter-over-quarter to $19.9B.
Based on VanEck Associates's 13F filing for Q4 2018, filed 12 Feb 2019.